PTC Therapeutics
PTCT
84 hedge funds and large institutions have $601M invested in PTC Therapeutics in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 8 closing their positions.
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
200% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 12
29% more funds holding
Funds holding: 65 → 84 (+19)
0% more capital invested
Capital invested by funds: $600M → $601M (+$661K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$12.9M |
| 2 |
Millennium Management
New York
|
+$9.57M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$9.13M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$5.1M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$25.7M |
| 2 |
Jennison Associates
New York
|
-$22.5M |
| 3 |
O
OrbiMed
New York
|
-$14M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$12.4M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.56M |
PTCT Hedge Fund Activity: Q2 2014 in Review
84 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2014, worth a combined $601M — up 0.11% from $600M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PTCT positions and 8 closed out — a net gain of 19 holders — while 36 added to existing stakes and 12 trimmed.
The largest buyer was Sectoral Asset Management, adding an estimated $12.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $25.7M sold.
- 84 institutional investors held PTC Therapeutics (PTCT) as of Q2 2014, up from 65 in Q1 2014.
- Funds reported $601M of PTC Therapeutics stock for Q2 2014, up 0.11% quarter-over-quarter.
- 27 funds opened new PTC Therapeutics positions in Q2 2014 and 8 closed out, a net change of +19 holders.
- The largest PTC Therapeutics buyer in Q2 2014 was Sectoral Asset Management, an estimated $12.9M added.
- The largest PTC Therapeutics seller in Q2 2014 was RA Capital Management, an estimated $25.7M sold.
Based on aggregated 13F filings for Q2 2014.